Manages levodopa/carbidopa. ANDA 206803, held by Rising Pharmaceuticals. Selegiline Hydrochloride.
As of Nov 21, 2026, ANDA 206803 (Selegiline Hydrochloride), held by Rising Pharmaceuticals, was first approved by FDA on Apr 2, 2019, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Selegiline capsules, USP are indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 2, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Selegiline Hydrochloride5MG · capsule;oral | Selegiline Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters